Literature DB >> 20687157

Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy.

Véronique Megalizzi1, Marie Le Mercier, Christine Decaestecker.   

Abstract

A large number of drugs are known to bind with high affinity to sigma receptors (sigma-Rs) and have been used in the clinic to treat mental disorders for many years. However, recent publications highlighting sigma-R overexpression in many cancer tissues suggest potential applications for sigma-R ligands in cancer diagnosis and therapy. The present review focuses on the involvement of sigma-Rs in cancer biology and the potential therapeutic contributions of their pharmacologic ligands in oncology. After summarizing the current and general knowledge regarding sigma-Rs, we detail data reported in the particular context of oncology. We then investigate the potential and specific signal transduction pathways and mechanisms involved in the actions of sigma-R ligands in cancer biology. These processes include modulations of (1) the plasma membrane and lipid raft components, (2) intracellular calcium levels, (3) cytoskeletal protein functions, and (4) endoplasmic reticulum stress. Finally, we conclude by speculating on the roles of sigma-R overexpression and sigma-R ligands in cancer biology and offer perspectives on cancer therapy.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687157     DOI: 10.1002/med.20218

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  20 in total

Review 1.  Development of (18)F-labeled radiotracers for neuroreceptor imaging with positron emission tomography.

Authors:  Peter Brust; Jörg van den Hoff; Jörg Steinbach
Journal:  Neurosci Bull       Date:  2014-08-29       Impact factor: 5.203

2.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

3.  Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells.

Authors:  Carmen Abate; John R Hornick; Dirk Spitzer; William G Hawkins; Mauro Niso; Roberto Perrone; Francesco Berardi
Journal:  J Med Chem       Date:  2011-07-20       Impact factor: 7.446

4.  Characterization of interactions of 4-nitrophenylpropyl-N-alkylamine with ς receptors.

Authors:  Uyen B Chu; Abdol R Hajipour; Subramaniam Ramachandran; Arnold E Ruoho
Journal:  Biochemistry       Date:  2011-08-09       Impact factor: 3.162

5.  Ether modifications to 1-[2-(3,4-dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine (SA4503): effects on binding affinity and selectivity for sigma receptors and monoamine transporters.

Authors:  Rong Xu; Sarah A Lord; Ryan M Peterson; Emily A Fergason-Cantrell; John R Lever; Susan Z Lever
Journal:  Bioorg Med Chem       Date:  2014-11-11       Impact factor: 3.641

Review 6.  Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.

Authors:  Srinivas Ramishetti; Leaf Huang
Journal:  Ther Deliv       Date:  2012-12

Review 7.  Current molecular imaging positron emitting radiotracers in oncology.

Authors:  Aizhi Zhu; Hyunsuk Shim
Journal:  Nucl Med Mol Imaging       Date:  2011-02-01

8.  Propellanes as Rigid Scaffolds for the Stereodefined Attachment of σ-Pharmacophoric Structural Elements to Achieve σ Affinity.

Authors:  Héctor Torres-Gómez; Constantin Daniliuc; Dirk Schepmann; Erik Laurini; Sabrina Pricl; Bernhard Wünsch
Journal:  Int J Mol Sci       Date:  2021-05-26       Impact factor: 5.923

Review 9.  The σ2 receptor: a novel protein for the imaging and treatment of cancer.

Authors:  Robert H Mach; Chenbo Zeng; William G Hawkins
Journal:  J Med Chem       Date:  2013-06-18       Impact factor: 7.446

10.  Antitumor activity of tumor-targeted RNA replicase-based plasmid that expresses interleukin-2 in a murine melanoma model.

Authors:  B Leticia Rodriguez; Jorge M Blando; Dharmika S P Lansakara-P; Yuriko Kiguchi; John DiGiovanni; Zhengrong Cui
Journal:  Mol Pharm       Date:  2013-05-17       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.